21 April 2022>: Articles
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
Unusual clinical course, Unusual or unexpected effect of treatment
Michael Cass A* , Andrew B. McDonald B , Osnat Ben-Shahar D , Yosef Landesman C , Trinayan Kashyap CDOI: 10.12659/AJCR.935353
Am J Case Rep 2022; 23:e935353
Figure 2. Changes in κ and λ serum free light chain levels (A) and in κ/λ ratio (B) during treatment with selinexor, bortezomib, and dexamethasone (XVd) and posttransplant (pT). sFLC – serum free light chain; Cx – Cycle x.